Managers / Q1 2019 · view latest →
SECTORAL ASSET MANAGEMENT INC
CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777
Reported Value
$831M
Q1 2019
Positions
106
Filings on Record
30
2019–present window
Filed
May 14, 2019
original filing
Summary
Sectoral Asset Management Inc reported $831M in U.S.-listed holdings across 106 positions for Q1 2019.
Its largest position, Amicus Therapeutics, represents 5.6% of the portfolio.
Compared with Q4 2018, the fund opened 13 new positions and exited 11.
Portfolio Metrics
Turnover
+12.9%
vs prior filed quarter
Top-10 Concentration
+37.2%
share of reported value
Largest Position
+5.6%
Amicus Therapeutics
New / Exited
13 / 11
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 87.3% · $726M
- Other · 9.9% · $83M
- ADR · 2.8% · $23M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2018 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SHOCKWAVE MEDICAL | NEW | +849.8K | 849.8K | +$28M | $28M |
| SRPTSAREPTA THERAPEUTICS | NEW | +128.1K | 128.1K | +$15M | $15M |
| MRKMERCK & CO INC | NEW | +164.7K | 164.7K | +$14M | $14M |
| ALLERGAN PLC | NEW | +84.9K | 84.9K | +$12M | $12M |
| FORTY SEVEN INC | NEW | +466.5K | 466.5K | +$8M | $8M |
| GLYCOMIMETICS INC | NEW | +548.0K | 548.0K | +$7M | $7M |
| INSPINSPIRE MED SYS INC | NEW | +85.9K | 85.9K | +$5M | $5M |
| FIBROGEN INC | NEW | +81.3K | 81.3K | +$4M | $4M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2019
106 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | AMICUS THERAPEUTICS | COM | 5.55% | $46M | 3.39M |
| 2 | AERIE PHARMACEUTIC | COM | 4.80% | $40M | 840.0K |
| 3 | ALNYALNYLAM PHARMACUETCLhistory → | COM | 4.40% | $37M | 391.0K |
| 4 | APELLIS PHARMACEUTIC | COM | 4.05% | $34M | 1.73M |
| 5 | TDOCTELADOC HEALTHhistory → | COM | 3.96% | $33M | 591.5K |
| 6 | SHOCKWAVE MEDICAL | COM | 3.42% | $28M | 849.8K |
| 7 | GILDGILEAD SCIENCES INChistory → | COM | 3.41% | $28M | 436.1K |
| 8 | ARRAY BIOPHARMA INC | COM | 2.67% | $22M | 910.0K |
| 9 | PORTOLA PHARMACEUTIC | COM | 2.54% | $21M | 609.4K |
| 10 | NVSNOVARTIS AGhistory → | SP ADR | 2.36% | $20M | 204.0K |
| 11 | PFEPFIZER INChistory → | COM | 2.14% | $18M | 419.1K |
| 12 | PTCTPTC THERAPEUTICS Ihistory → | COM | 2.10% | $17M | 463.1K |
| 13 | CELGCELGENE CORPhistory → | COM | 2.04% | $17M | 179.7K |
| 14 | HRCHILL-ROM HLDS INChistory → | COM | 2.02% | $17M | 158.8K |
| 15 | WRIGHT MED GROUP N V | ORD SHS | 1.90% | $16M | 501.3K |
| 16 | RA PHARMACEUTICALS | COM | 1.85% | $15M | 686.5K |
| 17 | SRPTSAREPTA THERAPEUTICShistory → | COM | 1.84% | $15M | 128.1K |
| 18 | EVHEVOLENT HEALTH INChistory → | COM | 1.82% | $15M | 1.20M |
| 19 | GLOBAL BLOOD THERA | COM | 1.74% | $14M | 273.3K |
| 20 | LLYLILLY ELI & COhistory → | COM | 1.74% | $14M | 111.5K |
| 21 | COLLCOLLEGIUM PHARMACEUThistory → | COM | 1.70% | $14M | 934.3K |
| 22 | ASSEMBLY BIOSCIENCES | COM | 1.70% | $14M | 715.8K |
| 23 | MRKMERCK & CO INChistory → | COM | 1.65% | $14M | 164.7K |
| 24 | XLRNACCELERON PHARMAhistory → | COM | 1.51% | $13M | 269.4K |
| 25 | ALLERGAN PLC | SHS | 1.50% | $12M | 84.9K |
| 26 | VOCERA COMMUNICATI | COM | 1.45% | $12M | 381.6K |
| 27 | LJPCLA JOLLA PHARMACLShistory → | COM | 1.36% | $11M | 1.76M |
| 28 | ATRCATRICURE INChistory → | COM | 1.27% | $11M | 393.1K |
| 29 | R1 RCM INC | COM | 1.26% | $11M | 1.09M |
| 30 | BMYBRISTOL MYERS SQUIBBhistory → | COM | 1.26% | $10M | 218.7K |
| 31 | MDTMEDTRONIC PLChistory → | SHS | 1.14% | $9M | 104.0K |
| 32 | BSXBOSTON SCIENTIFIChistory → | COM | 1.12% | $9M | 241.9K |
| 33 | PODDINSULET CORPhistory → | COM | 1.04% | $9M | 90.9K |
| 34 | TNDMTANDEM DIABETES CAREhistory → | COM | 1.04% | $9M | 135.7K |
| 35 | UNHUNITEDHEALTH GRP INChistory → | COM | 1.03% | $9M | 34.5K |
| 36 | VRAYQVIEWRAY INC | COM | 1.00% | $8M | 1.12M |
| 37 | OBSEVA SA | COM | 0.97% | $8M | 628.7K |
| 38 | BDQMALBIREO PHARMA INC | COM | 0.94% | $8M | 243.0K |
| 39 | ABTABBOTT LABS | COM | 0.94% | $8M | 97.6K |
| 40 | STEMLINE THERAPEUT | COM | 0.92% | $8M | 596.1K |
| 41 | FORTY SEVEN INC | COM | 0.91% | $8M | 466.5K |
| 42 | HMSYHMS HOLDINGS CORP | COM | 0.91% | $8M | 254.6K |
| 43 | BMRNBIOMARIN PHARMAC INC | COM | 0.86% | $7M | 80.3K |
| 44 | UNUM THERAPEUTICS | COM | 0.84% | $7M | 1.59M |
| 45 | GLYCOMIMETICS INC | COM | 0.82% | $7M | 548.0K |
| 46 | SVRASAVARA INC | COM | 0.79% | $7M | 896.2K |
| 47 | CICIGNA CORP | COM | 0.79% | $7M | 40.8K |
| 48 | ABIOMED INC | COM | 0.77% | $6M | 22.4K |
| 49 | IRTCIRHYTHM TECHNOLOGIES | COM | 0.74% | $6M | 82.6K |
| 50 | ZBHZIMMER BIOMET HLDS | COM | 0.73% | $6M | 47.7K |
| 51 | INTEC PHARMA LTD JER | SHS | 0.71% | $6M | 809.0K |
| 52 | NIGHTSTAR THERAPEU | ADR | 0.71% | $6M | 233.7K |
| 53 | ADAMAS PHARMACEUTI | COM | 0.69% | $6M | 808.9K |
| 54 | MEIRAGTX HLDINGS PLC | COM | 0.67% | $6M | 320.9K |
| 55 | MDGLMADRIGAL PHARMACEUTI | COM | 0.64% | $5M | 42.5K |
| 56 | EVELO BIOSCIENCES | COM | 0.63% | $5M | 651.1K |
| 57 | SAGE THERAPEUTICS | COM | 0.60% | $5M | 31.6K |
| 58 | INSPINSPIRE MED SYS INC | COM | 0.59% | $5M | 85.9K |
| 59 | FIBROGEN INC | COM | 0.53% | $4M | 81.3K |
| 60 | WELLCARE HEALTH PLAN | COM | 0.53% | $4M | 16.3K |
| 61 | AGIOAGIOS PHARMACEUTIC | COM | 0.49% | $4M | 60.0K |
| 62 | VRTXVERTEX PHARMACEUTICL | COM | 0.45% | $4M | 20.3K |
| 63 | EXKEXACT SCIENCES CORP | COM | 0.40% | $3M | 38.4K |
| 64 | SPRING BK PHARMACE | COM | 0.35% | $3M | 276.7K |
| 65 | PROTEOSTASIS THERA | COM | 0.31% | $3M | 2.05M |
| 66 | JNJJOHNSON & JOHNSON | COM | 0.30% | $2M | 17.8K |
| 67 | URGNUROGEN PHARMA LTD | COM | 0.29% | $2M | 65.1K |
| 68 | MOLECULAR TEMPLATES | COM | 0.24% | $2M | 350.0K |
| 69 | ONCBEIGENE LIMITED | SP ADR | 0.17% | $1M | 10.9K |
| 70 | TMOTHERMO FISHER SCI | COM | 0.15% | $1M | 4.5K |
| 71 | HCMHUTCHISON CHINA ME | SP ADR | 0.12% | $967,000 | 31.6K |
| 72 | ELVANTHEM INC | COM | 0.12% | $965,000 | 3.4K |
| 73 | RDYDR REDDYS LABS LTD | ADR | 0.10% | $798,000 | 19.7K |
| 74 | BDXBECTON DICKINSON | COM | 0.09% | $753,000 | 3.0K |
| 75 | HCAHCA HEALTHCARE | COM | 0.08% | $693,000 | 5.3K |
| 76 | DERMIRA INC | COM | 0.07% | $568,000 | 41.9K |
| 77 | KALVISTA PHARMACEUTI | COM | 0.06% | $502,000 | 17.6K |
| 78 | HUMHUMANA INC | COM | 0.06% | $490,000 | 1.8K |
| 79 | SPARK THERAPEUTICS | COM | 0.05% | $405,000 | 3.6K |
| 80 | UHSUNIVERSAL HEALTH SVC | CL B | 0.05% | $385,000 | 2.9K |
| 81 | ZLABZAI LAB LTD | ADR | 0.04% | $372,000 | 12.6K |
| 82 | BLUEPRINT MEDICINES | COM | 0.04% | $335,000 | 4.2K |
| 83 | ACELRX PHARMACEUTI | COM | 0.03% | $257,000 | 73.8K |
| 84 | CHEMOCENTRYX INC | COM | 0.03% | $247,000 | 17.8K |
| 85 | SIERRA ONCOLOGY INC | COM | 0.03% | $240,000 | 140.4K |
| 86 | CNCCENTENE CORP DEL | COM | 0.03% | $222,000 | 4.2K |
| 87 | MYOKARDIA INC | COM | 0.03% | $211,000 | 4.1K |
| 88 | BIOHAVEN PHARMACTL | COM | 0.02% | $201,000 | 3.9K |
| 89 | KURAKURA ONCOLOGY INC | COM | 0.02% | $196,000 | 11.8K |
| 90 | REVANCE THERAPEUTI | COM | 0.02% | $177,000 | 11.2K |
| 91 | QUOTIENT LTD | SHS | 0.02% | $159,000 | 17.6K |
| 92 | IMMUNOGEN INC | COM | 0.02% | $157,000 | 58.0K |
| 93 | ANTARES PHARMA INC | COM | 0.02% | $143,000 | 47.3K |
| 94 | PTGXPROTAGONIST THERAP | COM | 0.02% | $143,000 | 11.4K |
| 95 | MEI PHARMA INC | COM | 0.02% | $137,000 | 44.5K |
| 96 | CYTKCYTOKINETICS INC | COM | 0.02% | $126,000 | 15.6K |
| 97 | CTMXCYTOMX THERAPEUTIC | COM | 0.01% | $108,000 | 10.1K |
| 98 | AEGLEA BIOTHERAPEU | COM | 0.01% | $104,000 | 13.0K |
| 99 | NABRIVA THERAPEUTICS | SHS | 0.01% | $93,000 | 38.3K |
| 100 | ABEONA THERAPEUTICS | COM | 0.01% | $93,000 | 12.7K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $121M | 77 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $125M | 74 | Feb 9, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $162M | 82 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $151M | 94 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $128M | 84 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $150M | 86 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $169M | 90 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $246M | 97 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $254M | 92 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $232M | 104 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $514M | 123 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $600M | 121 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $520M | 118 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $517M | 120 | Feb 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $508M | 109 | Nov 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $496M | 112 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $563M | 106 | May 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $664M | 108 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.2B | 127 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.2B | 127 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.3B | 113 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.4B | 97 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $1.2B | 88 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $1.1B | 191 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $521M | 65 | May 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $670M | 65 | Feb 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $580M | 63 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $836M | 92 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $831M | 106 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $736M | 104 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.